Foresee doses first subject in Covid-19 ARDS treatment trial

Foresee Pharmaceuticals has started dosing patients in the Phase II/III clinical trial of its oral MMP-12 inhibitor, FP-025, to treat Covid-19 associated Acute Respiratory Distress Syndrome (ARDS).